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ABSTRACT
AIM: The BRAF mutation is a rare pathogenetic alternative to KIT/PDGFRA 
mutation in GIST and causes Imatinib resistance. A recent description of KIT and BRAF 
mutations co-occurring in an untreated GIST has challenged the concept of their being 
mutually exclusive and may account for ab initio resistance to Imatinib, even in the 
presence of Imatinib-sensitive KIT mutations. BRAF sequencing is generally limited 
to KIT/PDGFRA wild-type cases. Hence, the frequency of concomitant mutations may 
be underestimated. 
METHODS: We screened for KIT (exon 9, 11 ,13 ,17), PDGFRA (exon 12,14, 18) 
and BRAF (exon 15) mutations a series of 407 GIST. Additionally, we evaluated the 
BRAF V600E mutation-specific antibody, VE1, as a surrogate for V600E mutation, on 
a series of 313 GIST (24 on whole sections, 288  cases on tissue array), including 6 
cases molecularly ascertained to carry the BRAF V600E mutation.
RESULTS: No concomitant KIT/BRAF or PDGFRA/BRAF mutations were detected. 
BRAF mutation was detected only in one case, wild-type for KIT/PDGFRA. All the 6 
BRAF-mutant cases stained positive with the VE1 antibody. A weak VE1 expression 
was observed in 14/287 (4.9%) BRAF wild-type cases, as observed also in 2/6 BRAF-
mutant cases. Overall in our series, sensitivity and specificity  of the VE1 antobody 
were 100% and 95.1%, respectively. 
CONCLUSION: The concomitance of BRAF mutation with either KIT or PDGFRA 
mutation is rare in GIST. In these tumors, moderate/strong VE1 immunoreactivity is 
a valuable surrogate for molecular analysis. Instead, genotyping is warranted in the 
presence of weak VE1 staining. 
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INTRODUCTION
BRAF is a serine/threonine protein kinase of the 
RAF family and belongs to the RAS-RAF-MEK-ERK 
signalling pathway, which leads to the activation of several 
cytoplasmic and nuclear targets with transcriptional 
function, e.g. ETS11, c-JUN and c-MYC. This signalling 
pathway is triggered by several receptor tyrosine kinases 
(TKs) such as KIT and PDGFRA. In human cancer the 
RAS-RAF-MEK-ERK effector pathway is commonly 
activated, often with gain-of-function mutations in either 
RAS or RAF gene family members [1].
BRAF mutations have been found in a wide range 
of tumors (almost 7% of all cancers), both benign 
(melanocytic nevi [2], intestinal hyperplastic polyps, 
sessile serrated polyps/adenomas [3], gangliogliomas 
and pilocytic astrocytomas [4]), and malignant (hairy 
cell leukemia [5], melanomas [6], pleomorphic 
xanthoastrocytomas [4], papillary thyroid carcinomas [7], 
serous ovarian tumors [8], biliary tract carcinomas [9], 
colon adenocarcinomas [10, 11], lung adenocarcinomas 
[12], seminomas [13], mastocytosis [14] and 
gastroenteropancreatic neuroendocrine tumors [15]). 
The BRAF mutation has also been reported in a 
small subset of Gastrointestinal Stromal Tumors (GIST) 
[16].
GIST are the most common mesenchymal tumor 
of the gastrointestinal tract [16]. Around 85% of sporadic 
primary GIST harbor activating mutations in either the 
KIT (65%) or PDGFRA gene (20%) [17], both encoding 
type III RTKs, and are variably sensitive to RTK-
inhibitors, mainly Imatinib. The remaining cases (about 
15%) represent a heterogeneous group of tumors that 
generally do not respond to Imatinib and include pediatric 
GIST, SDH-deficient GIST, NF1-associated GIST, and 
GIST driven by mutations downstream the TK pathway, 
e.g. BRAF [16]. The BRAF mutation is a rare event in 
primary GIST. About 8% of the cases devoid of KIT/
PDGFRA mutations bear the BRAF mutation [17-21]. 
Although the use of next generation sequencing (NGS) 
mutation panels is gaining ground in the clinical diagnostic 
setting, in the majority of pathology laboratories molecular 
diagnosis still relies on Sanger sequencing and in most 
centers the BRAF mutation is investigated after ruling 
out the most common KIT and PDGFRA mutations. 
Hence, the frequency of this “alternative mechanism” 
and its co-existence with KIT/PDGFRA mutations 
is likely underestimated. BRAF-mutated tumors are 
morphologically and phenotypically indistinguishable 
from “classical” GIST. However, location-wise, they seem 
to cluster in the small bowel [17-21]. About 50% of the 
BRAF-mutated GIST reported so far fall in the AFIP high-
risk category [17-21]. Nevertheless, their rarity and the 
lack of follow-up data in most series leaves uncertainty as 
to the correlation between pathologic risk assessment and 
actual clinical behavior (See Table 1).
While the prognostic role of BRAF is still being 
debated, its predictive value in response to therapy is 
well documented. BRAF encodes a kinase molecule 
downstream of the TK pathways and its mutation 
constitutively activates the cascade, thereby bypassing the 
inhibitory effects of Imatinib. The BRAF mutation causes 
both ab initio resistance to imatinib treatment [19, 22] and 
secondary resistance when it occurs as a secondary event 
in KIT/PDGFRA-mutated GIST relapsing under therapy 
[19, 23]. Recently, a case of GIST with dual BRAF and 
KIT mutations has been reported in an untreated patient 
[21], challenging the concept of KIT/PDGFRA and BRAF 
mutation being mutually exclusive in primary GIST. 
These authors suggested that the concomitance of KIT and 
BRAF mutations might explain the resistance phenomena 
observed in a fraction of GIST carrying Imatinib-sensitive 
mutations (about 5%).
These combined data prompted us to perform a 
comprehensive evaluation of the involvement of BRAF 
kinase in GIST development and progression. To this 
end, we screened a series of 407 GIST cases referred 
to Treviso General Hospital. In addition, we sought to 
address the accuracy of immunohistochemistry-based 
screening to detect BRAF mutation as a surrogate for 
molecular analysis using BRAF V600E mutation-specific 
antibody VE1. This reagent has shown good sensitivity 
and specificity in detecting V600E-mutated cells in most, 
although not all, of the investigated tumor types [6, 24-49] 
[50] (See Supplementary Table 1). 
RESULTS
Results from KIT/PDGFRA/BRAF molecular 
analysis are summarized in Table 2. Only one out of the 
407 cases proved to carry a BRAF mutation. This case, 
a small intestinal untreated GIST, was devoid of KIT or 
PDGFRA mutations. No case of concomitant KIT and 
BRAF or PDGFRA and BRAF mutations was found, 
not even in relapsed cases. Conversely, six concomitant 
KIT/KIT and one concomitant KIT/PDGFRA mutations 
were detected in seven metastases that developed under 
Imatinib treatment (six peritoneal and one hepatic) 
(Table 3). This supports the notion that BRAF activation 
compensates for lack of TK mutation in GIST but does 
not seem to play a relevant role in secondary resistance, 
where KIT exon 13 and exon 17 mutations seem to be 
prevalent, in line with published data [16]. In addition, a 
double mutation was found in a localized untreated rectal 
GIST; in this case, both mutations involved KIT exon 11 
(Lys558Gln and Val560del). 
As for the immunohistochemical results, VE1 
antibody yielded weak, non-specific, diffuse cytoplasmic 
staining in the normal gastric/intestinal epithelium and 
muscularis propria. No nuclear reactivity was observed. A 
clear-cut positive pattern, with fine granular cytoplasmic 
accumulation was evident in all four BRAF-mutated 
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Table 1: BRAF-mutated GIST in the literature
N° Ref. Age/Sex Primary/ Relapsed Site
Size 
(cm) Morph.
Mit./ 
50HPF
AFIP 
Risk 
1 Agaram 52/F Primary Sm. Int. 10 Mixed 90 HR
2 Agaram 55/F Primary Sm. Int. 10 Spindle 5 LR
3 Agaram 49/F Primary Sm. Int. 9 Mixed 50 HR
4 Agaram 66/M Relapsed** Perit.. NA Rhabdo NA NA
5 Agaimy 70/M Primary Stom. 0.4 Spindle <5 NR
6 Agaimy 80/M Primary Sm. Int. 0.4 Spindle <5 NR
7 Hostein 53/M Primary Sm. Int. 20 Spindle 6 HR
8 Hostein 38/M Primary Sm. Int. 2.5 Mixed 5 IR
9 Hostein 63/M Primary Stom. 2.5 Spindle NA NA
10 Hostein 78/M Primary Stom. NA Spindle 1 LR
11 Hostein 51/F Primary Sm. Int. 3 Spindle 10 HR
12 Hostein 58/M Primary Duod. 2.5 Mixed 1 IR
13 Hostein 58/M Primary Sm. Int. 2.5 Spindle 6 IR
14 Hostein 41/M Primary Sm. Int. 2.5 Spindle 3 LR
15 Hostein 50/F Primary Perit. 2.8 Epith. 50 HR
16 Miranda NA Primary Sm. Int. NA NA NA HR
17 Miranda NA Primary NA NA NA NA NA
18 Falchook 60 M Primary NA 15 Spindle 6* NA
19 Zheng 75 M Relapsed** Perit. NA Rhabdo 8 NA
20 Rossi 69/M Primary Sm. Int. 4.6 Spindle 4 LR
21 Rossi 36/F Primary Sm. Int. 8.5 Mixed 3 UR
22 Rossi 66/F Primary Sm. Int. 5.4 MixedPolym. 8 HR
23 Rossi 63/M Primary Sm. Int. 11.2 Mixed 12 HR
24 Rossi 42/F Primary Sm. Int. 3.8 Spindle 7 HR
25 Rossi (current) 89/F Primary Sm. Int. 1.8 Spindle 1 NR
Sm. Int.= Small Intestine; Stom.= Stomach; Duod.= Duodenum; Perit.= Peritoneum; Rhabdo= Rhabdomyoblastic 
differentiation; Polym.= Polymorphic; HR= High Risk; IR= Intermediate Risk; LR= Low Risk; NR= No Risk; UR= Unknown 
Risk; 
 * In this case the number of mitoses was counted on 10 HPF; ** Tumor developed under imatinib therapy;
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control GIST and the single V600E-mutated case 
included in our series. This reactivity was weak in two 
cases, moderate in one and strong in two cases (Figure 
1A-1E), with a prevalent homogeneous pattern, but for 
one case where it was patchy. No reactivity was observed 
in BRAF wild-type cases. Overall, there was complete 
agreement in this study series (21 cases) between BRAF 
V600E molecular analysis and IHC, with a sensitivity and 
specificity of 100% (Table 4). 
To corroborate this initial finding, a second set of 
288 GIST, belonging to a population-based study and 
arranged in tissue arrays, was also analysed. The single 
BRAF-mutant case included in this series turned out to be 
positive for VE1, with moderate granular staining of the 
cytoplasm (Fig. 1 F). Two hundred and seventy-three cases 
were clearly negative. Conversely, weak cytoplasmic-
positive staining was observed in 14 cases, three of which 
belonged to the KIT/PDGFRA/BRAF wild-type subgroup, 
seven to the KIT-mutated and four to the PDGFRA-
mutated subgroup. Negativity for BRAF mutation was 
double checked in these cases. In this second study set, 
the concordance rate between BRAF V600E molecular 
analysis and IHC was thus 95.1%, with a sensitivity of 
100% and specificity of 95.1% (Table 4). Importantly, 
none of the BRAF-wild-type GIST showed moderate/
strong staining.
Table 2: Frequency of KIT/PDGFRA/BRAF mutations in 407 GIST cases
Gene Exon Cases (N) Cases (%)
KIT 11 243 59.7
KIT 9 39 9.6
KIT 13 11 2.7
KIT 17 3 0.8
PDGFRA 18 37 9.1
PDGFRA 12 6 1.5
PDGFRA 14 4 1
BRAF 15 1 0.2
KIT/PDGFRA/BRAF WT - 55 13.5
KIT/KIT 11/11 1 0.2
KIT/KIT 11/13 2* 0.5
KIT/KIT 11/17 3* 0.8
KIT/KIT 13/17 1* 0.2
KIT/PDGFRA 13/18 1* 0.2
Total - 407 100.0
*Imatinib-treated GIST with double mutations
Table 3: Cases with secondary mutations developed under Imatinib therapy
Primary tumor Metastasis
Site Gene/exon Mutation Site Gene/exon Mutation
1 NA KIT/11 Met552_Pro573delinsIle abdominal cavity KIT/17 Tyr823Asp
2 stomach KIT/11 Trp557_Glu561del abdominal cavity KIT/13 Val654Ala
3 NA KIT/11 Asn566_Pro573del abdominal cavity KIT/17 Asn822Lys
4 duodenum KIT/11 Val560_Leu576del Liver KIT/13 Met651Ile
5 NA KIT/11 Glu556_Val560delinsHis abdominal cavity KIT/17 Asn822Lys
6 stomach KIT/13 Lys642Glu abdominal cavity KIT/17 Asn822Lys
7 stomach KIT/13 Lys642Glu abdominal cavity PDGFRA/18 Arg841_Asp842delinsLys
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Figure 1: All six BRAF V600E-mutated GIST of the series were VE1 positive, with weak cytoplasmic staining in two 
cases (A,B), moderate staining in two cases (C, F) and strong staining in two cases (D, E)..
Table 4: VE1 sensitivity and specificity in the first and second study set
Whole section set TMA set
Cases 25 288
BRAF-mutated cases 5 1
BRAF-mutated VE1-positive cases
(% sensitivity)
5
(100)
1
(100)
BRAF-WT VE1-positive cases
(% specificity)
0
(100)
14
(95.1)
Sensitivity = 100.00 %  (95% CI: 16.55 % to 100.00 %)
Specificity = 95.12 %  (95% CI: 91.95 % to 97.31 %)
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DISCUSSION
BRAF mutation has been reported in a small subset 
of primary KIT and PDGFRA wild-type GIST [17-21] and 
in rare relapsed cases receiving Imatinib therapy [19, 23]. 
To date, 22 BRAF-mutated cases have been described, but 
the actual role of V600E mutation in GIST pathobiology 
is far from being defined. Except for a few studies [17, 
18, 20, 21], BRAF status is usually investigated in KIT/
PDGFRA mutation-negative cases only.
To investigate the relevance of concomitant BRAF 
and KIT/PDGFRA mutations in primary and secondary 
resistance to Imatinib, we conducted a molecular study of 
the hot spots of KIT, PDGFRA and BRAF. Only one case 
out of the 407 analyzed GIST carried the BRAF V600E 
mutation. This case was wild-type for KIT/PDGFRA. 
No concomitant mutations were found in KIT and BRAF 
or PDGFRA and BRAF. We detected only one double 
mutation in a localized/untreated context, consisting of a 
point mutation and a deletion affecting nearby nucleotides 
in KIT exon 11, similarly to our previous report [51]. 
Secondary mutations in KIT-mutated cases involved the 
more classical tyrosine kinase domains of KIT (exon 13 
and 17) in six out of seven cases. Intriguingly, we also 
found one gastric GIST with a primary KIT exon 13 
mutation (Lys642Glu) which relapsed three years later 
under Imatinib, with a secondary mutation in PDGFRA 
exon 18 (Arg841_Asp842delinsLys). To the best of our 
knowledge, this is the second case reported so far of 
acquired resistance involving a different kinase from the 
one affected by the primary mutation [52]. Our results 
support the notion that the BRAF mutation plays a minor 
role as a concomitant alteration in both primary and 
secondary resistance.
In order to optimize the method for detecting BRAF-
mutated cases in GIST, we evaluated the expression of 
the mutation-specific antibody VE1 in a large series of 
GIST and compared the results with direct sequencing of 
BRAF exon 15. Our findings indicate that VE1 antibody is 
highly sensitive for the presence of BRAF V600E mutation 
in GIST, as all six BRAF-mutated cases scored VE1 
positive with moderate/strong staining intensity in four 
cases. Moderate/strong staining was detected exclusively 
in BRAF-mutated GIST, whereas none of the BRAF-
mutation negative cases displayed such intensity. These 
findings indicate that significantly intense VE1 staining 
reliably predicts the presence of BRAF mutation. This is 
in line with a recent study on a series of 38 GIST, in which 
VE1 strong expression was limited to the 2 BRAF-mutant 
cases included [53]. Additionally, in that series, a weak 
VE1 staining was found only in a fraction of the BRAF-
mutation negative cases [53]. Differently, in our series, 2 
out of 6 BRAF-mutant cases showed only a weak VE1 
staining, as well as 14 out of 287 (4.9%) BRAF wild-type 
cases. Hence, our results should caution the pathologist to 
interpret as either negative or positive for BRAF-mutation 
those GIST that show a weak VE1 expression. Instead, we 
consider that in presence of a weak staining, the molecular 
assessment of BRAF gene status is highly recommended.
Although the frequency of the BRAF mutation in 
GIST is limited (<1%), the presence of this mutation has 
a high impact on patients’ management. If on one hand it 
causes resistance to TK-inhibitors [18, 22], on the other 
it sensitizes the tumor to BRAF inhibitors. Falchook et 
al. recently reported a GIST case effectively treated with 
Dabrafenib [22]. NGS is gaining ground in the diagnostic 
setting, thus allowing for the simultaneous assessment 
of a wider set of molecular biomarkers. While waiting 
for this approach to be fully implemented by pathology 
laboratories, we believe that at the present time VE1 
immunostaining may represent a valuable tool to address 
BRAF mutation status in GIST. 
MATERIALS AND METHODS
Tumor samples 
To investigate the role of BRAF mutation in GIST, 
KIT (exon 9, 11, 13, 17), PDGFRA (exon 12, 14, 18) and 
BRAF (exon 15) mutations were sequenced in a series 
of 407 cases (including 358 personal consultation cases 
referred to one of the authors [ADT], and 49 in-house 
cases) from 398 patients. Eight patients had multiple GIST 
either in the context of neurofibromatosis (three cases) or 
in a non-syndromic context (five cases) [54]. Informed 
consent was obtained from all living patients. Two hundred 
and fifteen were men and 183 were women. Age ranged 
between 24 and 91 years (median 63). Clinical records 
were available for 344 of the 398 patients. Two hundred 
and eighty-seven out of 353 tumors were primary GIST: 
262 located in the gastrointestinal tract (142 gastric, 17 
duodenal, 88 from the small intestine, one from the colon, 
14 from the sigma-rectum) and 23 extra-gastrointestinal 
(12 from the abdominal cavity and pelvis, and nine from 
the retro-peritoneum). The remaining 68 cases were either 
relapsed or metastatic GIST.
The median size of the primary tumors was 5.5 
cm (range 0.5 to 35 cm) and the median mitotic index 
was 4/50 HPF (range 0 to 180). The risk category 
could be determined in 221 cases on the basis of the 
AFIP classification (17 no risk, 13 very low, 61 low, 49 
intermediate and 81 high risk tumors). 
The predictive value of VE1 staining, as a surrogate 
for BRAF mutation analysis, could be assessed by 
immunohistochemistry on a subset of 21 (in-house) cases. 
Four GIST carrying the BRAF V600E mutation were 
retrieved from a previous series [17] and included as 
positive controls. 
A further series of 288 cases, arranged in 25 tissue 
microarrays (TMA) deriving from a large population-
Oncotarget7www.impactjournals.com/oncotarget
based Italian study [17] [55], was also tested for VE1. 
Each tumour was represented by two to four cores in 
each array. In this study set, KIT/PDGFRA/BRAF status 
had previously been determined by sequential screening 
of the different exons until the mutation was detected, in 
the following order: KIT exon 11, KIT exon 9, PDGFRA 
exon 18, PDGFRA exons 12 and 14, KIT exons 13 and 
17. Cases devoid of KIT/PDGFRA mutation were further 
investigated for BRAF V600 mutations [17]. Of these 
288 cases, one was BRAF-mutated (V600E), 188 were 
KIT-mutated (165 with exon 11, 18 with exon 9, three 
with exon 13 and two with exon 17 mutation), 61 were 
PDGFRA-mutated (49 with exon 18, five with exon 14, 
six with exon 12 mutation), one case carried a double 
KIT mutation (Asn659Asp and Pro567Leu), and 38 were 
wild-type. Three of the 165 KIT exon 11 mutations were 
homozygous. 
Molecular analyses
DNA was extracted from representative blocks of 
formalin-fixed/paraffin-embedded tissues with tumor 
cellularity greater than 80%. 10-μm-thick sections were 
deparaffinized by serial xylene/ethanol washings. DNA 
was extracted using the EZ1 Biorobot (Qiagen GmbH). 
KIT, PDGFRA and BRAF mutation analysis was 
performed by PCR and Sanger sequencing using the ABI 
PRISM 3100 Genetic Analyzer (Applied Biosystems), as 
previously described [17] [51] [54].
Immunohistochemistry
Immunohistochemistry (IHC) was performed on 
freshly-cut 3-μm-thick, paraffin-embedded tissue sections, 
using VE1 antibody specific for BRAF V600E mutation 
(clone VE1, Spring Bioscence, Pleasanton, CA). Only 
cases for which the block was available to provide freshly 
cut sections were included in the study. To optimize the 
method, a range of conditions were tested, in relation to 
both antibody dilution (1:25, 1:50, 1:100) and antigen 
retrieval (pH6 and pH9 buffer). A series of 10 melanomas, 
eight with V600E mutation and two with alternative 
BRAF mutations (V600K, K601E), were used as positive 
and negative control cases, respectively. 
The selected protocol included heat-induced epitope 
retrieval (PTLINK Dako) with high pH (pH9) and antigen-
antibody reaction at 1:100 dilution for 40 minutes (KIT 
ENVISION FLEX, Dako) in an automated immunostainer 
(Dako Autostainer, DakoCytomation, Glostrup, Denmark). 
For four BRAF-mutated cases, VE1 antibody was also 
tested on whole sections which had been cut seven 
years earlier. Notably, the intensity of the staining was 
much weaker than the results obtained on the freshly-cut 
sections, highlighting that the time gap between cutting 
and staining highly impacts on VE1 performance.
All immunostained slides were evaluated with 
blinding to clinical, histopathologic and genetic data 
by three histopathologists of varying experience. 
Interobserver agreement was high with approximately 
10% of the cases re-reviewed collegially. Where there 
was any disagreement, the sections were re-reviewed and 
a consensus opinion reached. 
Tumors were considered as positive when the 
tumor cells showed weak, moderate or strong cytoplasmic 
staining, and as negative when the tumor cells showed 
either faint cytoplasmic staining or no staining. 
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